The estimated Net Worth of Jonathan P Northrup is at least 564 千$ dollars as of 11 February 2020. Jonathan Northrup owns over 8,700 units of Salarius Pharmaceuticals stock worth over 564,341$ and over the last 5 years Jonathan sold SLRX stock worth over 0$.
Jonathan has made over 1 trades of the Salarius Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently Jonathan bought 8,700 units of SLRX stock worth 10,005$ on 11 February 2020.
The largest trade Jonathan's ever made was buying 8,700 units of Salarius Pharmaceuticals stock on 11 February 2020 worth over 10,005$. On average, Jonathan trades about 2,175 units every 0 days since 2019. As of 11 February 2020 Jonathan still owns at least 352,713 units of Salarius Pharmaceuticals stock.
You can see the complete history of Jonathan Northrup stock trades at the bottom of the page.
Jonathan's mailing address filed with the SEC is C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOMBE BLVD., SUITE J - 608, HOUSTON, TX, 77021.
Over the last 5 years, insiders at Salarius Pharmaceuticals have traded over 0$ worth of Salarius Pharmaceuticals stock and bought 487,662 units worth 209,636$ . The most active insiders traders include David J. Arthur、Mark J Rosenblum、Arnold C Hanish. On average, Salarius Pharmaceuticals executives and independent directors trade stock every 40 days with the average trade being worth of 33,925$. The most recent stock trade was executed by Tess Burleson on 7 June 2022, trading 27,700 units of SLRX stock currently worth 4,986$.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and potential biomarkers for Seclidemstat (SP-2577). Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Salarius Pharmaceuticals executives and other stock owners filed with the SEC include: